- Pharmaron reported a net income of 1.79 billion yuan for the fiscal year 2025.
- The net income result was very close to the analysts’ estimate of 1.81 billion yuan.
- The company’s revenue matched expectations at 12.28 billion yuan.
- Investor sentiment towards the company remains positive.
- The stock has 19 buy recommendations from analysts.
- There are 4 hold recommendations for the company’s stock.
- Only 2 analysts have issued sell recommendations.
A look at Pharmaron Beijing Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 4 | |
| Resilience | 3 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Pharmaron Beijing Co., Ltd. is positioned for a promising long-term trajectory according to Smartkarma’s Smart Scores. The company has solid marks in Growth and Resilience, with a score of 4 and 3 respectively. This indicates that Pharmaron Beijing is expected to experience healthy expansion opportunities and possess the ability to withstand challenges. These factors bode well for the company’s future prospects.
However, there are areas where Pharmaron Beijing has room for improvement. The company’s Momentum score, at 2, suggests some sluggishness in its short-term performance. While both Value and Dividend scores stand at a respectable 3, there may be potential for enhancement in these areas. Overall, with a combination of positive growth and resilience indicators, Pharmaron Beijing appears to be well-positioned for sustainable development in the foreseeable future.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
